Please use this identifier to cite or link to this item:
The Competitive Strategy of Taiwan Prescription Drug Supplier in Pharmacy Channel - A Case study of SPL Company
prescription drugs,pharmaceutical,competitive strategy,
|Publication Year :||2019|
The pharmaceutical industry is a highly regulated industry in Taiwan. Since the implementation of universal health insurance in 1995 and the implementation of pharmaceutical separation in 1997, the pharmaceutical industry has undergone considerable changes, and the pharmaceutical industry has been rapidly developed due to its inclusion in health insurance. Twenty years have passed since the past ten years, the government has continuously lowered the amount of health care drug prices for years to reduce health care financial expenditures. In this regard, the operation and transformation of the domestic health insurance pharmacy is also facing great challenges. In particular, how drug suppliers should develop their own business strategies is the main topic of this research. This study uses the customer case analysis method to find out the key factors of success through the five-force analysis and evaluation model, and then makes a comparative analysis based on the resource capabilities of the case company and proposes the competition strategy. The results are listed as follows:
1. The pharmaceutical industry is affected by the health insurance fiscal tightening policy, the overall supply chain profits continue to shrink, and drug suppliers need to tap the new blue ocean to enter the niche market.
2. SPL can continue to strive for the source of competitive advantage by different strategies, such as differentiation, low cost and centralization, in order to escape the existing market Red Sea.
3. Through the integration of cross-disciplinary expertise and the inclusiveness of corporate culture.
|Appears in Collections:||事業經營碩士在職學位學程|
Files in This Item:
|2.52 MB||Adobe PDF|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.